drugset / Trial / NCT01833065

Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic Constipation

NCT01833065

Phase 3 Terminated 314 enrolled Ferring Pharmaceuticals
RandomizedParallel-groupDouble-blindTreatment

Summary

12 Week Efficacy and Safety Trial Followed by a 4 Week Withdrawal Period for Patients with Chronic Idiopathic Constipation.

Timeline

Start
2013-04
Primary completion
2014-03
Completion
2014-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Elobixibat Small molecule 5 mg
Subject Elobixibat Small molecule 10 mg

Indications